Glucagon-like peptide-1 in type 2 diabetes: The β-cell and beyond

Diabetes, Obesity and Metabolism

Volumn 10, Issue SUPPL. 3, 2008, Pages 2-13

  Nauck, Michael A ^a  

^a DIABETESZENTRUM BAD LAUTERBERG   (Germany)

Author keywords

DPP 4 inhibitors; GLP 1; GLP 1 agonists; Incretins

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; CANNABINOID 1 RECEPTOR ANTAGONIST; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 AGONIST; GLUCOSE; HUMAN INSULIN; INCRETIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; LIRAGLUTIDE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PRAMLINTIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; VILDAGLIPTIN;

CELL FUNCTION; CLINICAL TRIAL; DIABETOGENESIS; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; EDEMA; GASTROINTESTINAL DISEASE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART PROTECTION; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RELEASE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OFF LABEL DRUG USE; PANCREAS ISLET CELL; PREGNANCY DIABETES MELLITUS; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN MANIFESTATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 47649131890     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00919.x     Document Type: Review

References (59)

1. UK Prospective Disease Study Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
2. UK Prospective Disease Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
3. Wajchenberg BL. Beta cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28: 187-218.
4. Buchanan TA. Pancreatic beta cell loss and preservation in type 2 diabetes. Clin Ther 2003; 25(Suppl. B): B32-B46.
5. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004; 88: 787-835.
6. Kahn SE. The importance of beta cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 4047-4058.
7. Utzschneider KM, Prigeon RL, Carr DB et al. Impact of differences in fasting glucose and glucose tolerance on the hyperbolic relationship between insulin sensitivity and insulin responses. Diabetes Care 2006; 29: 356-362.
8. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: Measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981; 68: 1456-1467.
9. Nathan DM, Davidson MB, Dr Fronzo RA et al. Impaired fasting glucose and impaired glucose tolerance: Implications for care. A Consensus Statement from the American Diabetes Association. Diabetes Care 2007; 30: 753-759.
10. Pratley RE, Matfin G. Pre-diabetes: Clinical relevance and therapeutic approach. Br J Diabetes Vasc Dis 2007; 7: 120-129.
11. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1988; 40 (Suppl.): S21-S25.
12. Butler AE, Janson J, Bonner-Weir A, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
13. Mecce J. Pancreatic islet dysfunction in type 2 diabetes: A rational target for incretin-based therapies. Curr Med Res Opin 2007; 23: 933-944.
14. Drucker DJ. The biology of incretin hormones. J Cell Metab 2003; 3: 153-165.
15. Degn KB, Juhl CB, Sturis J et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 1187-1194.
16. Mitrakou A, Kelley D, Veneman T et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 1990; 39: 1381-1390.
17. International Diabetes Federation. Diabetes Atlas, 2nd edn. Available from URL: http://www.atlas.idf.org/. Accessed 22 May 2008
18. Cowie CC, Rust KF, Byrd-Holt DD et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population. National Health and Nutrition Examination Survey. Diabetes Care 2006; 29: 1263-1268.
19. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-974.
20. Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-544.
21. Shaw JE, Zimmet PZ, de Courten M et al. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius. Diabetes Care 1999; 22: 399-402.
22. Wajchenberg BL. Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697-738.
23. Gerich JE. The genetic basis of diabetes mellitus: Impaired insulin secretion vs. impaired insulin sensitivity. Endocr Rev 1998; 19: 491-503.
24. Inzucchi S. Oral hypoglycaemic therapy for type 2 diabetes. JAMA 2002; 287: 360-372.
25. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13 (Suppl. 1): 1-68.
26. Blonde L, Rosenstock J, Triplitt C et al. What are incretins, and how will they influence the management of type 2 diabetes? J Manag Care Pharm 2006; 12 (7 Suppl. A): S2-S12.
27. Amori RE, Lau J, Pittas AG et al. Efficacy and safety of incretin therapy in type 2 diabetes. JAMA 2007; 298: 194-206.
28. McIntyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet 1964; ii: 20-21.
29. Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24: 1076-1082.
30. Baggio L, Drucker J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157.
31. La Barre J. Sur les possibilitiés d'un traitement du diabète par l'incrétine. Bull Acad R Med Belg 1932; 12: 620-634.
32. Drucker DJ. Glucagon-like peptides: Regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003; 17: 161-171.
33. Garber A. GLP-1-based therapies: New developments and emerging data. Diabetes Obes Metab 2008; 10(Suppl. 3): 22-35.
34. Gutzwiller JP, Drewe J, Göke B et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276: R1541-R1544.
35. Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-498.
36. Nauck MA, Stöckmann F, Ebert R et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
37. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: A parallel-group study. Lancet 2002; 359: 824-830.
38. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
39. Zander M. The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes. Diabetologia 2006; 49: 369-374.
40. Vilsbøll T, Knop FK, Krarup T et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide -regardless of etiology and phenotype. J Clin Endocrinol Metab 2003; 88: 4897-4903.
41. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
42. Bregenholt S, Moldrup A, Knudsen LB, Petersen JS. The GLP-1 derivative NN2211 inhibits cytokine-induced apoptosis in primary rat beta-cells. Diabetes 2001; 50 (Suppl. 2): A31.
43. Sturis J, Gotfredsen CF, Rømer J et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: Influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003; 140: 123-132.
44. Chang AM, Jakobsen G, Sturis J et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003; 52: 1786-1791.
45. Li Y, Cao X, Li LX et al. Beta-cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 2005; 54: 482-491.
46. Xu G, Stotters DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-2276.
47. Kolterman OG, Buse JB, Fineman MS et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-3089.
48. Fehse FC, Trautmann M, Holst JJ et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 5991-5997.
49. Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004; 53: 2181-2189.
50. Holst JJ. The physiology and pharmacology of incretins in type 2 diabetes mellitus. Diabetes Obes Metab 2008; 10 (Suppl. 3): 14-20.
51. Vilsbøll T, Zdravkovic M, Le-Thi T et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 1608-1610.
52. Mari A, Sallas WM, He YL et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-4894.
53. Nikolaidis LA, Mankad S, Sokos GG et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109: 962-965.
54. Nyström T, Gutniak MK, Zhang Q et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287: E1209-E1215.
55. Vilsbøll T, Zdravkovic M, Le-Thi T et al. Liraglutide treatment, blood pressure and biomarkers of cardiovascular risk in patients with type 2 diabetes: 14 weeks monotherapy study. Diabetes 2006; 55 (Suppl. 1): A465.
56. Kendall D, Blonde L, Mac S et al. Improvements in cardiovascular risk factors accompanied improved glycemic control and weight reduction in patients with type 2 diabetes treated with exenatide for 3.5 y. Diabetes 2007; 57 (Suppl. 1): A149.
57. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005; 54: 146-151.
58. Vilsboll T. Liraglutide: A once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 2007; 16: 231-237.
59. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-2940.